Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5571912 | 0.89 | EPHX2 (0.40) | CA2EPHX2NR1H4GAAKDM4E | |
| SCHEMBL4773098 | 0.82 | GAA (0.43) | CA2GAACA1NAMPTSMN1; SMN2 | |
| SCHEMBL4773019 | 0.80 | GAA (0.46) | CA2EPHX2NR1H4GAAKDM4E | |
| SCHEMBL5568007 | 0.80 | GAA (0.46) | CA2EPHX2NR1H4GAAKDM4E | |
| SCHEMBL4776124 | 0.80 | GAA (0.44) | CA2GAACA1NAMPTSMN1; SMN2 | |
| SCHEMBL5571908 | 0.77 | GAA (0.43) | CA2EPHX2NR1H4GAAKDM4E | |
| SCHEMBL4775048 | 0.76 | GAA (0.70) | EPHX2NR1H4GAAALDH1A1NAMPT | |
| SCHEMBL4776622 | 0.76 | GAA (0.44) | CA2EPHX2NR1H4GAAKDM4E | |
| SCHEMBL5572009 | 0.76 | GAA (0.44) | CA2EPHX2NR1H4GAAKDM4E | |
| SCHEMBL4776528 | 0.74 | GAA (0.62) | CA2GAAALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1942888-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-07-16 | — | — | EP | claimed |
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-14 | — | — | US | claimed |
| WO-2007056078-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| EP-1942888-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| WO-2007056078-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CA2 2238/4885EPHX2 2831/4885NR1H4 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.